Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas

Clinical and Experimental Metastasis

Volumn 25, Issue 1, 2008, Pages 75-80

  Rhomberg, Walter ^a   Eiter, Helmut ^a   Schmid, Franz ^b   Saely, Christoph H ^b,c  

^a ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c VIVIT Institut   (Austria)

Author keywords

Anti angiogenic drugs; Anti metastatic treatment; Combined modality treatment; Radiosensitizing agents; Razoxane; Soft tissue sarcomas; Vindesine

Indexed keywords

MITOXANTRONE; RAZOXANE; VINDESINE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; ESOPHAGITIS; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MALE; METASTASIS INHIBITION; NAUSEA; NEUROTOXICITY; PNEUMONIA; PROGNOSIS; SOFT TISSUE SARCOMA; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM METASTASIS; PILOT PROJECTS; RADIOTHERAPY; RAZOXANE; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; VINDESINE;

EID: 38849099155     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-007-9103-9     Document Type: Article

References (28)

1. Rhomberg W, Hassenstein EOM, Gefeller D (1996) Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. Int J Radiat Oncol Biol Phys 36:1077-1084
2. Rhomberg W, Eiter H, Schmid F, Saely CH (2007) Razoxane and vindesine in advanced soft tissue sarcomas: impact on metastasis, survival and radiation response. Anticancer Res 27(5)
3. De Vita VT Jr, Hellman S, Rosenberg SA (eds) (2001) Cancer principles & practice of oncology. JB Lippincott Comp, Philadelphia, pp 1879-1883
4. Storme GA, Schallier DC, De Neve WJ et al (1988) Vinblastine has radiosensitizing activity in limited squamous cell lung cancer. Int J Radiat Oncol Biol Phys 15(Suppl 1):222
5. Rhomberg W, Eiter H, Soltesz E et al (1990) Long term application of vindesine: toxicity and tolerance. J Cancer Res Clin Oncol 116:651-653
6. Atassi G, Dumont P, Vandendris M (1982) Investigation of the in vivo anti-invasive and anti-metastatic effect of desacetyl vinblastine amide sulphate or vindesine. Invasion Metastasis 2:217-231
7. Mareel MM, Bracke ME, Boghaert ER (1986) Tumor invasion and metastasis: therapeutic implications? Radiother Oncol 6:135-142
8. Haug IJ, Siebke EM, Grimstad IA et al (1993) Simultaneous assessment of migration and proliferation of murine fibrosarcoma cells, as affected by hydroxyurea, vinblastine, cytochalasin B, razoxane and interferon. Cell Prolif 26:251-261
9. Mareel MM, Storme GA, De Bruyne GK et al (1982) Vinblastin, vincristine and vindesine: antiinvasive effect on MO4 mouse fibrosarcoma cells in vitro. Eur J Cancer Clin Oncol 18:199-210
10. Hellmann K, Murkin GE (1974) Synergism of ICRF 159 and radiotherapy in the treatment of experimental tumors. Cancer 34:1033-1039
11. Tanabe K, Ikegami Y, Ishida R, Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51:4903-4908
12. Karakiulakis G, Missirlis E, Maragoudakis ME (1989) Mode of action of razoxane: inhibition of basement membrane collagen-degradation by a malignant tumor enzyme. Methods Find Exp Clin Pharmacol 11:255-261
13. Hellmann K, Burrage K (1969) Control of malignant metastases by ICRF 159. Nature 224:273-275
14. Le Serve AW, Hellmann K (1972) Metastases and the normalization of tumor blood vessels by ICRF-159: a new type of drug action. Br Med J 1:597-601
15. Hellmann K (2003) Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown. Clin Exp Metastasis 20:95-102
16. Salsbury AJ, Burrage K, Hellmann K (1974) Histological analysis of the antimetastatic effect of 1,2-Bis (3,5-dioxo-piperazin-1-yl)-propane. Cancer Res 34:843-849
17. Baker D, Constable W, Elkon D, Rinehart L (1981) The influence of ICRF 159 and levamisole on the incidence of metastases following local irradiation of a solid tumor. Cancer 48:2179-2183
18. Peters LJ (1975) A study of the influence of various diagnostic and therapeutic procedures applied to a murine squamous carcinoma on its metastatic behaviour. Br J Cancer 32(3):355-365
19. Antman K, Crowley J, Balcerzak SP et al (1993) An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285
20. Edmonson JH, Ryan LM, Blum RH et al (1993) Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275
21. Santoro A, Tursz T, Mouridsen H et al (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first line treatment of advanced soft tissue sarcomas: a randomized study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545
22. Rööser B, Attewell R, Berg NO, Rydholm A (1988) Prognostication in soft tissue sarcoma. A model with four risk factors. Cancer 61:817-823
23. Zagars GK, Ballo MT, Pisters PWT et al (2003) Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 57:739-747
24. Komdeur R, Hoekstra HJ, van den Berg E et al (2002) Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. Cancer Metastasis Rev 21:167-183
25. Kerbel RS (2001) Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 19(Suppl):45s-51s
26. Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24
27. Hofland KF, Thougaard AV, Dejligbjerg M et al (2005) Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin Cancer Res 11:6722-6729
28. D'Adamo DR, Anderson SE, Albritton K et al (2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23:7135-7142